RBC names Gilead a top biotech pick based on valuation


A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

David Paul Morris | Bloomberg | Getty Images

Now is a good entry point into Gilead’s stock as the company begins to stabilize, while still trading at a discount to its peers, according to RBC Capital Markets.

The firm named biotechnology company Gilead to its top picks list and maintained its $91 price target, a near 34% upside.

Products You May Like

Articles You May Like

Bitcoin Falls Through Key Average as Traditional Markets Hit Record Highs
After Dow tops 28,000, the next 1,000 points will be determined by trade talks
Binance Gets Banned on Weibo as China Continues Crypto Crackdown
HTC Will Support Binance Chain With Special Edition Smartphone
Nuveen moves to introduce new evidence in its defense against anti-competitive allegations

Leave a Reply

Your email address will not be published. Required fields are marked *